BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Recruiting now · Phase 1/Phase 2

Conditions studied: Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer

In brief

This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.

Key facts

Study ID
NCT07193511
Run by
Avenzo Therapeutics, Inc.
People needed
355
Starts
2025-10-02
Expected to finish
2030-09-01
Last updated by the study team
2026-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.